There are several options to optimize therapy of severe atopic asthma (SAA) patients who do not achieve sufficient control of asthma. One of them is to use biological products (Bx). Omalizumab is a representative of Bx indicated for SAA treatment. But usually Bx therapy is initiated in hospital that is increasing the total cost of the treatment

OBJECTIVES: The purpose of this work was to conduct a comparative pharmacoeconomic analysis of omalizumab using for treatment of SAA patients in hospital (established practice) and in outpatient settings.

METHODS: “Budget impact analysis” of SAA patients treated with omalizumab based on retrospective data of case stories of 32 SAA patients from specialized hospital departments in the Irkutsk region from July 2013 to December 2017. Two types of disease management have been assessed: hospital settings and outpatient settings. Totally 127 clinical cases were analyzed. Structure of direct costs included the costs of drugs, medical service and hospitalization are based on the tariff agreement of territorial obligatory medical insurance fund for the Irkutsk region, a program of state guarantees for free provision of medical care to citizens for 2016 - 2017, public procurement of medicines for asthma treatment, data of the state register of medicinal products.

RESULTS: The study demonstrated that the introduction of out-patient use of omalizumab therapy will allow a 77% reduction of total costs for SAA treatment. The decrease in the number of inpatient hospitalizations for patients with atopic asthma, the confirmed safety of outpatient administration, including the initiation of Bx therapy, are sources of additional financial savings.

CONCLUSIONS: Thus, treatment with omalizumab of SAA patients in Russia allows to optimize and rationally distribute budget funds of territorial healthcare systems and medical organizations.